Is bradycardia in dengue fever clinically significant?

Is Bradycardia in Dengue Fever Bad?

Bradycardia in dengue fever is clinically significant and should prompt cardiac evaluation, as it represents one of the most common cardiac manifestations of dengue and is associated with underlying cardiac involvement that predicts adverse outcomes.

Clinical Significance of Bradycardia in Dengue

Bradycardia occurs in approximately 11-20% of dengue patients and represents the most frequent arrhythmia in this infection 12. While often transient and self-limited, its presence signals potential cardiac involvement that warrants attention.

Key Evidence on Prognostic Value

Cardiac involvement in dengue occurs in 12-50% of hospitalized patients, with arrhythmias being among the most frequent cardiac manifestations alongside pericarditis, myocarditis, and myocardial dysfunction 333. Critically, any abnormality on echocardiography has been associated with adverse outcomes in dengue patients 3333333.

A large study of 320 dengue patients found that all 14 patients who died had ECG abnormalities, including bradycardia, demonstrating 100% negative predictive value for the absence of ECG changes 4. This means that while bradycardia alone may not directly cause death, its presence indicates a subset of patients at higher risk.

Understanding the Pattern

• Sinus bradycardia (heart rate <60 bpm) is paradoxical given the presence of fever, making it particularly noteworthy 24
• Most commonly occurs around illness day 10, during the critical/recovery phase 5
• Occurs more frequently in adults (30%) compared to children (10.7%) 1
• Often accompanies other cardiac abnormalities including elevated troponin (15%), reduced ejection fraction <40% (13%), and elevated CK-MB (10.6%) 4

Risk Stratification Approach

High-Risk Features Requiring Cardiac Evaluation

When bradycardia is present, assess for these additional risk factors that predict cardiac involvement 6:

• Age >60 years (3-fold increased risk)
• Warning signs (severe abdominal pain, persistent vomiting, bleeding, lethargy)
• Laboratory markers:
  • Thrombocytopenia
  • Anemia
  • Elevated creatinine
  • Hypoalbuminemia
  • Elevated D-dimer (6-fold increased risk)

Recommended Evaluation

For patients with bradycardia in dengue:

1. Baseline 12-lead ECG - document rhythm, PR interval, QRS duration, QTc interval
2. Cardiac biomarkers - troponin T/I, CK-MB, NT-pro BNP 4
3. Echocardiography if any of the following:
   • Elevated cardiac biomarkers
   • Additional ECG abnormalities beyond isolated bradycardia
   • Clinical signs (chest pain, dyspnea, syncope)
   • High-risk features listed above
   • Severe dengue classification

Important Clinical Nuances

When Bradycardia is Relatively Benign

In young adults without comorbidities presenting with non-severe dengue and isolated sinus bradycardia without other ECG changes or elevated biomarkers, the finding is often transient and clinically insignificant 5. A study of 136 predominantly young Vietnamese adults found that routine ECGs in non-severe dengue provided limited clinically actionable information 5.

When to Worry

Bradycardia becomes concerning when accompanied by:

• Conduction abnormalities (PR prolongation, AV blocks, QRS changes) - associated with longer hospitalization and increased morbidity 7
• ST-T wave changes (seen in 2-8% of patients) 52
• Symptoms (chest pain, dyspnea, syncope)
• Severe dengue classification (hemorrhage, plasma leakage, organ dysfunction)
• Pediatric population - higher incidence of cardiac complications reported 333
• Male sex - higher rates of LV systolic dysfunction 333

Common Pitfalls to Avoid

1. Underdiagnosis: Cardiovascular complications are significantly underdiagnosed in endemic areas where only a small percentage of dengue patients receive cardiac evaluation 3333

2. Dismissing as benign: While most bradycardia is transient, assuming all cases are benign without risk stratification can miss serious cardiac involvement

3. Missing myocarditis: Dengue myocarditis can mimic myocardial infarction and rarely trigger coronary thrombosis, dissection, or intramural hematoma 333

4. Inadequate monitoring: The critical phase (days 4-7) and early recovery phase (days 8-10) are when cardiac manifestations peak 5

Practical Management Algorithm

For all dengue patients with bradycardia:

• Document with 12-lead ECG
• Check cardiac biomarkers (troponin, CK-MB)
• Assess for warning signs and severe dengue criteria

If isolated bradycardia + young + non-severe dengue + normal biomarkers:

• Clinical monitoring sufficient
• Repeat ECG if clinical deterioration

If bradycardia + any high-risk feature:

• Echocardiography
• Serial cardiac biomarkers
• Consider cardiology consultation
• Closer monitoring for hemodynamic instability

The bottom line: Bradycardia in dengue is a marker of cardiac involvement that requires risk stratification rather than routine dismissal, as it identifies a subset of patients at higher risk for adverse outcomes including mortality.